Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-Hodgkin's lymphoma?

Bone Marrow Transplantation

Volumn 32, Issue 6, 2003, Pages 569-573

  Jantunen, Esa ^a   Kuittinen, T ^a   Nousiainen, T ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chemotherapy score; Non Hodgkin's lymphoma; Progenitor cell mobilisation

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ARABINOSIDE; BLEOMYCIN; CD34 ANTIGEN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOGUAZONE; MITOXANTRONE; PREDNISOLONE; PROCARBAZINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; BLOOD CELL COUNT; CELL DAMAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; STEM CELL MOBILIZATION; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0141725750     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704184     Document Type: Article

References (22)

1. Gratwohl A, Passweg J, Baldomero H et al. Hematopoietic stem cell transplant activity in Europe 1999. Bone Marrow Transplant 2001; 27: 899-916.
2. Gratwohl A, Baldomero H, Horisberger B et al for The Accreditation Committee of The European Group for Blood and Marrow Transplantation (EBMT). Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002; 100: 2374-2386.
3. Haas R, Möhle R, Fruhauf S et al. Patient characteristics associated with successful mobilization and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
4. Drake M, Ranaghan L, Morris TCM et al. Analysis of the effect of prior chemotherapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745-749.
5. Clark RE, Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859-863.
6. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
7. Reiter A, Schrappe M, Parwaresh R et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995; 13: 359-372.
8. Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803-3809.
9. Aurlien E, Holte H, Pharo A et al. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 873-878.
10. McQuaker I, Haynes A, Stainer C et al. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Bone Marrow Transplant 1999; 24: 715-722.
11. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-3785.
12. Dormer P, Sauer H, Shalhorn A, Willmanns W. Differential effect of high-dose methotrexate on erythropoiesis and granulocytopoiesis in humans. Cancer Res 1982; 42: 1604-1697.
13. Guigon M, Izumi-Hisha H, Mary J-Y. Long-term effects of high-doses of cytosine arabinoside on pluripotents stem cells (CFU-S). Exp Hematol 1989; 17: 203-207.
14. Laszlo D, Galieni P, Raspadori D et al. Fludarabine-containing regimens may adversely affect peripheral blood stem cell collection in low-grade lymphoma patients. Leuk Lymphoma 2000; 37: 157-161.
15. Ketterer N, Salles G, Moullet I et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235-242.
16. Koumakis G, Vassilomanolakis M, Hatzichristou H et al. Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single aphaeresis (SA) for rescuing patients after high-dose chemotherapy (HD.CHE) in various malignancies. Bone Marrow Transplant 1996; 18: 1065-1072.
17. Morton J, Morton A, Bird R et al. Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate-dose cyclophosphamide and G-CSF. Leukemia Res 1997; 21: 21-27.
18. Vantelon JM, Koscielny S, Brault P et al. Scoring system for the prediction of successful blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice. Bone Marrow Transplant 2000; 25: 495-499.
19. Neben S, Hemman S, Montgomery M et al. Haematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 1993; 21: 156-162.
20. Gardner RV, Lerner C, Astle CM, Harrison DE. Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay. Cancer Chemother Pharmacol 1993; 32: 450-454.
21. Roberts AW, DeLuca E, Begley CG et al. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995; 13: 512-516.
22. Kessinger A, Sharp JG. The whys and hows of hematopoietic progenitor stem cell mobilization. Bone Marrow Transplant 2003; 31: 319-329.